Loading
A phase 1/2 trial of bevacizumab (glioblastoma use) and regorafenib in colorectal cancer, run by CSPC Megalith Biopharmaceutical Co.,Ltd., not yet recruiting.
A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer is a phase 1/2, randomised interventional study registered as NCT07750041 by CSPC Megalith Biopharmaceutical Co.,Ltd., with a registry enrolment figure of 260 participants, started 2026-08-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: SYS6090 (Fixed Dose Level A) + bevacizumab; SYS6090 (Fixed Dose Level B ) + bevacizumab; SYS6090 RP2D + bevacizumab +mFOLFOX6; SYS6090 RP2D + bevacizumab; Regorafenib; SYS6090 PR2D+ bevacizumab + FOLFOXIRI; bevacizumab + FOLFOXIRI. Conditions listed: Unresectable Advanced or Metastatic Colorectal Cancer. Primary outcome: Recommended Phase 2 Dose (RP2D), Safety and Tolerability; Objective Response Rate (ORR) assessed per RECIST v1.1; Progression-Free Survival (PFS) assessed per RECIST v1.1. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed unresectable advanced or metastatic colorectal cancer with pMMR/MSS status, assigned to corresponding cohorts as follows:". Sites: China. No results are recorded here; the registry entry is the source.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Bevacizumab (glioblastoma use), Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), Anti-angiogenic therapy, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Regorafenib, Anti-angiogenic therapy, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.